A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

NCT01351103 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
BRAF Mutant Colorectal Cancer
Melanoma
Triple Negative Breast Cancer
Head and Neck Squamous Cell Cancer
Cervical Squamous Cell Cancer
Esophageal Squamous Cell Cancer
Lung Squamous Cell Cancer

Interventions

DRUG: LGK974
BIOLOGICAL: PDR001

Sponsor

Novartis Pharmaceuticals